Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.
The improved long-term survival of adolescents and young women treated for cancer has resulted in an increased focus on the effects of chemotherapy on ovarian function and its preservation. These women may seek advice and treatment regarding their reproductive status, including ways of preserving their fertility and preventing a premature menopause--factors that can have a profound impact on their quality of life. This article comprehensively reviews ovarian reserve testing (ORT) in general. Special emphasis is placed on patients with cancer, including the pathophysiology of gonadal damage following chemotherapy, fertility preservation and the potential role of ORT. Baseline parameters of ovarian reserve [FSH LH, estradiol, inhibin B and anti-Mullerian hormone (AMH)] have not yet performed sufficiently well in predicting poor outcome in assisted reproduction, but biochemical markers of ovarian reserve appear to be better than chronological age. Inhibin B and AMH show potential for future use. Dynamic testing appears to show much promise, especially stimulated levels of inhibin B and estradiol. The most promising tests of ovarian reserve are the biophysical markers, where total antral follicle count was found to be most discriminatory followed by ovarian volume. Combination of biochemical, biophysical and clinical markers of ovarian reserve may also improve predictive capacity. However, there is a lack of data pertinent to ORT in cancer. As yet there is no single clinically useful test to predict ovarian reserve accurately. Patients with cancer represent a distinct cohort who have particular concerns about their future fertility and the possibility of a premature menopause, they can benefit greatly from knowledge of their functional ovarian reserve. Large, prospective, randomized, adequately controlled studies specific to different geographical areas are required in a control population of comparable reproductive age to determine the potential role of ORT in clinical practice.
Lutchman Singh
Kerryn
K
Department of Obstetrics and Gynaecology, Reproductive Medicine Unit, Elizabeth Garrett Anderson and Obstetric Hospital, University College London Hospital, Huntley Street, London WC1E 6DH, UK. k.lutchman-singh@ucl.ac.uk
Davies
Melanie
M
Chatterjee
Ratna
R
D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D015925:Cryopreservation; D004622:Embryo, Mammalian / Q000502:physiology; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D009369:Neoplasms / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D009865:Oocytes / Q000502:physiology; D010053:Ovary / Q000000981:diagnostic imaging / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D011247:Pregnancy; D014021:Tissue Preservation / Q000379:methods; D014463:Ultrasonography / Q000379:methods
D015415:Biomarkers